These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20853592)

  • 21. Simeprevir (Olysio) for chronic hepatitis C.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):1-3. PubMed ID: 24419295
    [No Abstract]   [Full Text] [Related]  

  • 22. [Victrelis and Incivek against hepatitis C: some promising options].
    Sabourin G
    Perspect Infirm; 2012; 9(1):58-9. PubMed ID: 22295460
    [No Abstract]   [Full Text] [Related]  

  • 23. Thrombotic microangiopathy (TMA) in a patient treated with antiviral therapy for hepatitis C.
    Evans R; Pavan M; Suri D; Harber M
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24706704
    [No Abstract]   [Full Text] [Related]  

  • 24. Future therapies for hepatitis C: where do we go from here?
    Sigal S; Jacobson I
    Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):60-1. PubMed ID: 17268539
    [No Abstract]   [Full Text] [Related]  

  • 25. New Merck and Vertex drugs raise standard of care in hepatitis C.
    Sheridan C
    Nat Biotechnol; 2011 Jul; 29(7):553-4. PubMed ID: 21747363
    [No Abstract]   [Full Text] [Related]  

  • 26. Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis.
    de Kanter CT; den Hollander JG; Verweij-van Wissen CP; Burger DM
    J Clin Virol; 2014 Aug; 60(4):431-2. PubMed ID: 24929751
    [No Abstract]   [Full Text] [Related]  

  • 27. [Protease inhibitors--new preparations for treatment of HIV infections].
    Lundgren JD
    Ugeskr Laeger; 1998 Jan; 160(4):451-6. PubMed ID: 9463265
    [No Abstract]   [Full Text] [Related]  

  • 28. New therapies for hepatitis C.
    Modi AA; Hoofnagle JH
    Hepatology; 2007 Sep; 46(3):615-7. PubMed ID: 17879364
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical trial investigates two experimental HCV drugs.
    AIDS Patient Care STDS; 2010 Apr; 24(4):270. PubMed ID: 20402017
    [No Abstract]   [Full Text] [Related]  

  • 30. [Introduction].
    Romero Gómez M
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():1. PubMed ID: 24063895
    [No Abstract]   [Full Text] [Related]  

  • 31. [When and how should hepatitis C be treated?].
    Färkkilä M
    Duodecim; 2010; 126(1):41-8. PubMed ID: 20405608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Septic bursitis, a potential complication of protease inhibitor use in hepatitis C virus.
    Burke CC; Martel-Laferriere V; Dieterich DT
    Clin Infect Dis; 2013 May; 56(10):1507-8. PubMed ID: 23413416
    [No Abstract]   [Full Text] [Related]  

  • 33. Headache associated with telaprevir treatment.
    Moncada AC; Puebla A; Badia E; Sáez-Royuela F
    Headache; 2014 Jan; 54(1):168-9. PubMed ID: 24400757
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of hepatitis C--update 2005].
    Forestier N; Zeuzem S
    Dtsch Med Wochenschr; 2005 Dec; 130 Suppl 5():S215-6. PubMed ID: 16435713
    [No Abstract]   [Full Text] [Related]  

  • 35. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients.
    Peres-da-Silva A; de Almeida AJ; Lampe E
    Arch Virol; 2010 May; 155(5):807-11. PubMed ID: 20405151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The management of hepatitis C.
    Pan JJ; Firpi RJ
    Minerva Gastroenterol Dietol; 2009 Mar; 55(1):23-35. PubMed ID: 19212305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
    Seden K; Back D; Khoo S
    J Antimicrob Chemother; 2010 Jun; 65(6):1079-85. PubMed ID: 20335191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL28B testing in a rapidly changing world: Still relevant?
    King LY; Chung RT
    J Hepatol; 2013 May; 58(5):847-9. PubMed ID: 23416431
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis C infection and lymphomas: is there any benefit in viral treatment?
    Bruni L; De Sanjose S
    Gastroenterology; 2006 Aug; 131(2):685-6; author reply 686-7. PubMed ID: 16890632
    [No Abstract]   [Full Text] [Related]  

  • 40. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.